Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat ...

As of February 2025, the semaglutide injection (Ozempic, Wegovy) shortage was resolved. As a result, compounded semaglutide ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Novo Nordisk trades 32% below fair value with a 3.6% yield, semaglutide at 74% of sales, EPS rebound post '26, and pipeline ...

Topline data from the phase 3 ATTAIN-MAINTAIN trial evaluated orforglipron for weight maintenance after initial treatment with Wegovy or Zepbound in adults with obesity or overweight.

Have you ever searched for information about side effects of a medication? These days, most people put the name of their drug into a search engine along with the phrase “side effects.” Whatever comes ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients. Semaglutide is Novo Nordisk's largest growth driver, and it has not performed ...

In November 2025, US President Donald Trump announced transformative actions to lower prescription drug costs and secure the ...

How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...